AstraZeneca PLC Ordinary Shares (NYSE: AZN)
According to the Complaint, Astrazeneca PLC is a multinational biopharmaceutical company and was one of the early front-runners in the race to develop a COVID-19 vaccine. In April 2020, the Company partnered with Oxford University to develop a potential recombinant adenovirus vaccine for the virus, later dubbed AZD1222.